ALCOX.PA

NicOx S.A.

ALCOX.PA, France

Nicox S.A., together with its subsidiaries, operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. The company's lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. It also develops NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals that is in Phase 2b clinical trial for the treatment of dry eye disease; and NCX 1728, an NO-donating phosphodiesterase-5 inhibitor, which is in preclinical evaluation. In addition, the company offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular related associated with allergic conjunctivitis. Nicox S.A. was founded in 1996 and is headquartered in Biot, France.

https://www.nicox.com

Stock Price

€0.00

0%

increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
ALCOX.PA
stock
ALCOX.PA

Nicox Announces Conference Attendance in H1 2026 and Upcoming Scientific Data Presentations Yahoo Finance UK

Read more →
ALCOX.PA
stock
ALCOX.PA

Analysts Expect Nicox S.A. (EPA:ALCOX) To Breakeven Soon simplywall.st

Read more →

Showing 2 of 4

Analyst Ratings & Sentiment

(Last Updated 2023-12-31)

Rating:

STRONG BUY

$

Analyst Picks

Strong Buy

1

Buy

0

Hold

0

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2023-12-31)

Health Score

Price to Book Ratio (P/B)

-

Very Low

0.84

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-97.48 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-39.40 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

0.12 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

1.47

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 0.00% of the total shares of NicOx S.A.

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2026-03-31

EPS Estimate

—

Latest Release

Date

2025-12-31

EPS Actual

—

EPS Estimate

-0.05

EPS Difference

0

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2023-12-31)

Deep Value
Potential Value Candidate(6)
Defensive
Moderately Defensive(6)
Dividend
Weak Dividend Profile(3)
Economic Moat
Some Competitive Advantage(4.8)
GARP
Fair GARP(5)
Growth
Moderate Growth(4.5)
Momentum
Moderate Momentum(4)
Net Net
Not Undervalued (Net-Net)(3)
Quality
Moderate Quality(3.5)
Value
Fair Value(4.5)

Income Statement

(Last Updated 2023-12-31)

Revenue

€ 0

Cost Of Revenue

€ 0

Gross Profit

€ 0

Operating Expenses

€ 0

Operating Income

€ 0

Interest Expense

€ 0

Pretax Income

€ 0

Net Income

€ 0

Income Tax Expense

€ 0

EBITDA

€ 0

Total Other Income Expense Net

€ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2023-12-31)

Cash

€ 0

Short Term Investments

€ 0

Receivables

€ 0

Inventories

€ 0

Total Current Assets

€ 0

Property Plant Equipment

€ 0

Total Assets

€ 0

Payables

€ 0

Short Term Debt

€ 0

Long Term Debt

€ 0

Total Liabilities

€ 0

Equity

€ 0

Trend

Cash Flow

(Last Updated 2023-12-31)

Net Income

€ 0

Depreciation

€ 0

Change In Working Capital

€ 0

Cash From Operations

€ 0

Capital Expenditures

€ 0

Cash From Investing

€ 0

Cash From Financing

€ 0

Net Change In Cash

€ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.